Professor of Medicine
Member of the Duke Cancer Institute
Campus mail
Box 3381, Seeley Mudd Building, Durham, NC 27710
Phone
(919) 471-8344
Email address
carey.anders@duke.edu
Education and Training
- Hematololgy-Oncology Fellowship, Medicine, Duke University School of Medicine, 2005 - 2008
- Internal Medicine Residency, Medicine, Duke University School of Medicine, 2002 - 2005
- M.D., East Carolina University, Brody School of Medicine, 2002
Grants
- A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF-07284890 (ARRY-461) IN PARTICIPANTS WITH BRAF V600-MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT
- An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Br
- A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors
- ABL-regulated transcriptional and epigenetic networks promote outgrowth of breast cancer metastases revealing novel therapeutic targets
- ABL-regulated transcriptional and epigenetic networks promote outgrowth of breast cancer metastases revealing novel therapeutic targets
- R01 Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis
- A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician's Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)
- Retrospective tissue study HER2-positive breast cancer prediction of brain metastasis
- T32 UNC - Duke Immunotherapy Training Program
- Discovery and validation of putative oncogenic ROS1 alterations in metastatic breast cancer
- Dr. Anders-Cancer Research